JP5615189B2 - ベリノスタットの長期持続注入を用いた治療方法 - Google Patents

ベリノスタットの長期持続注入を用いた治療方法 Download PDF

Info

Publication number
JP5615189B2
JP5615189B2 JP2010549210A JP2010549210A JP5615189B2 JP 5615189 B2 JP5615189 B2 JP 5615189B2 JP 2010549210 A JP2010549210 A JP 2010549210A JP 2010549210 A JP2010549210 A JP 2010549210A JP 5615189 B2 JP5615189 B2 JP 5615189B2
Authority
JP
Japan
Prior art keywords
cancer
long
intravenous infusion
disease
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010549210A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011513378A (ja
JP2011513378A5 (https=
Inventor
セヘステッド，マクスウェル
ブール ジェンセン，ピーター
ブール ジェンセン，ピーター
ニッセン，ニス
Original Assignee
トポターゲット アー／エス
トポターゲット アー／エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トポターゲット アー／エス, トポターゲット アー／エス filed Critical トポターゲット アー／エス
Publication of JP2011513378A publication Critical patent/JP2011513378A/ja
Publication of JP2011513378A5 publication Critical patent/JP2011513378A5/ja
Application granted granted Critical
Publication of JP5615189B2 publication Critical patent/JP5615189B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2010549210A 2008-03-07 2009-03-06 ベリノスタットの長期持続注入を用いた治療方法 Active JP5615189B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3463508P 2008-03-07 2008-03-07
US61/034,635 2008-03-07
PCT/IB2009/005044 WO2009109861A1 (en) 2008-03-07 2009-03-06 Methods of treatment employing prolonged continuous infusion of belinostat

Publications (3)

Publication Number Publication Date
JP2011513378A JP2011513378A (ja) 2011-04-28
JP2011513378A5 JP2011513378A5 (https=) 2012-04-19
JP5615189B2 true JP5615189B2 (ja) 2014-10-29

Family

ID=40691318

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010549210A Active JP5615189B2 (ja) 2008-03-07 2009-03-06 ベリノスタットの長期持続注入を用いた治療方法

Country Status (14)

Country Link
US (1) US20110003777A1 (https=)
EP (1) EP2262493B1 (https=)
JP (1) JP5615189B2 (https=)
CN (1) CN102083428A (https=)
AU (1) AU2009220942B2 (https=)
CA (1) CA2717207A1 (https=)
DK (1) DK2262493T3 (https=)
EA (1) EA022880B1 (https=)
ES (1) ES2536208T3 (https=)
MX (1) MX2010009642A (https=)
PL (1) PL2262493T3 (https=)
PT (1) PT2262493E (https=)
SI (1) SI2262493T1 (https=)
WO (1) WO2009109861A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011064663A1 (en) 2009-11-25 2011-06-03 Festuccia, Claudio Combination treatment employing belinostat and bicalutamide
CA2871061C (en) * 2012-04-27 2017-06-20 Sun Pharmaceutical Industries Ltd Ready to be infused gemcitabine solution
CN103839548B (zh) * 2012-11-26 2018-06-01 腾讯科技（北京）有限公司 一种语音交互方法、装置、系统和移动终端

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642316A (en) * 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
US6071923A (en) * 1994-09-16 2000-06-06 Bar-Ilan University Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
US20020025921A1 (en) * 1999-07-26 2002-02-28 Petito George D. Composition and method for growing, protecting, and healing tissues and cells
BR9914779A (pt) * 1998-10-13 2001-07-03 Fujisawa Pharmaceutical Co Composto wf27082, processo para sua produção, composição farmacêutica contendo o mesmo, cepa de fundos pertencente ao gênero acremonium, composto tendo atividade inibidora de desacetilase de histona, processo para sua produção, seu método e uso
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
EP1179541B1 (en) * 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
KR20020070285A (ko) * 1999-11-23 2002-09-05 메틸진, 인크. 히스톤 디아세틸라제의 억제제
CA2423744C (en) * 2000-09-29 2012-04-03 Prolifix Limited Hydroxamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
GB0023983D0 (en) * 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
EP1335898B1 (en) * 2000-09-29 2005-11-23 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
JPWO2002074298A1 (ja) * 2001-03-21 2004-07-08 小野薬品工業株式会社 Ｉｌ−６産生阻害剤
MXPA04001253A (es) * 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
US6897220B2 (en) * 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
NZ533737A (en) * 2002-01-11 2006-02-24 Matthias Rath A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
US20050288227A1 (en) * 2002-02-15 2005-12-29 Marks Paul A Use of thioredoxin measurements for diagnostics and treatments
JP2005525345A (ja) * 2002-02-15 2005-08-25 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｔｒｘ媒介性疾患を処置する方法
WO2003075839A2 (en) * 2002-03-04 2003-09-18 Aton Pharma, Inc. Methods of inducing terminal differentiation
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
WO2003087066A1 (en) * 2002-04-11 2003-10-23 Sk Chemicals, Co., Ltd. α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
CN100566711C (zh) * 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
US20050222013A1 (en) * 2003-01-16 2005-10-06 Georgetown University Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy
CA2518318A1 (en) * 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
KR100924737B1 (ko) * 2003-08-26 2009-11-04 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｄａｃ 억제제를 이용한 암의 치료 방법
EP1689445B1 (de) * 2003-11-14 2015-02-25 Per Sonne Holm Neue verwendung von adenoviren und dafür codierende nukleinsäuren
EP1689446B1 (de) * 2003-11-14 2015-01-07 Per Sonne Holm Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
GB0401876D0 (en) * 2004-01-28 2004-03-03 Vereniging Het Nl Kanker I New use for cancer antigen
ATE437370T1 (de) * 2004-02-27 2009-08-15 Us Gov Health & Human Serv Pharmakodynamische tests mit durchflusszytometrie
ES2308065T3 (es) * 2004-04-30 2008-12-01 Topotarget Germany Ag Formulacion que comprende un inhibidor de histona desacetilasa, que exhibe una liberacion bifasica.
JPWO2006014024A1 (ja) * 2004-08-06 2008-05-01 小野薬品工業株式会社 精神神経系疾患治療剤
KR20070057822A (ko) * 2004-08-09 2007-06-07 아스텔라스세이야쿠 가부시키가이샤 히스톤 디아세틸라제 (ｈｄａｃ) 억제제 활성을 갖는히드록시아미드 화합물
WO2006060382A2 (en) * 2004-11-30 2006-06-08 Trustees Of The University Of Pennsylvania Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
EP1830864A2 (de) * 2004-12-31 2007-09-12 Per Sonne Holm E1 -minus adenoviren und deren verwendung
MX2007008781A (es) * 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
NZ589276A (en) * 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
US20060229237A1 (en) * 2005-04-07 2006-10-12 Yih-Lin Chung Treatment of gastrointestinal distress
GB0509225D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
CN101189003B (zh) * 2005-05-13 2012-02-08 托波塔吉特英国有限公司 Hdac抑制剂的药物制剂
EP1743654A1 (en) * 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
US20080292616A1 (en) * 2005-08-19 2008-11-27 Government Of The United Of America, Represented By The Secretary, Department Of Health And.... Topical Formulations of Histone Deacetylase Inhibitors and Methods Using the Same
KR20080042170A (ko) * 2005-09-07 2008-05-14 플렉시콘, 인코퍼레이티드 Ｐｐａｒ 활성 화합물
JP5377968B2 (ja) * 2005-11-10 2013-12-25 トポターゲット ユーケー リミテッド 癌治療のために単独で用いるまたは化学療法薬と併用するヒストンデアセチラーゼ（ｈｄａｃ）阻害剤
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
MX2008010799A (es) * 2006-02-22 2008-11-06 4Sc Ag Indolopiridinas como moduladores de quinesina eg5.
EP3862354A1 (en) * 2006-02-22 2021-08-11 4Sc Ag Indolopyridines as eg5 kinesin modulators
EP1839656A1 (en) * 2006-03-31 2007-10-03 TopoTarget Germany AG Use of valproic acid for the topical treatment of mild to moderate acne vulgaris
WO2007129062A1 (en) * 2006-05-08 2007-11-15 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
EP2040731A4 (en) * 2006-06-09 2010-05-19 Merrion Res Iii Ltd SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
US8338482B2 (en) * 2006-07-20 2012-12-25 Wisconsin Alumni Research Foundation Modulating notch1 signaling pathway for treating neuroendocrine tumors
WO2008058287A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
WO2008094319A2 (en) * 2007-02-01 2008-08-07 The Board Of Regents Of The University Of Texas Sytem Methods and compositions of trail-death receptor agonists/activators
WO2008101121A2 (en) * 2007-02-14 2008-08-21 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to promoter regulation by muc1 and klf proteins
WO2008136838A1 (en) * 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
EP2167090A4 (en) * 2007-06-06 2010-08-25 Univ Maryland HDAC INHIBITORS AND HORMONE TREATMENT MEDICAMENTS
WO2009146034A2 (en) * 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
WO2009137649A2 (en) * 2008-05-07 2009-11-12 The Trustees Of The University Of Pennsylvania Methods for treating thyroid cancer

Also Published As

Publication number Publication date
JP2011513378A (ja) 2011-04-28
DK2262493T3 (en) 2015-04-27
EA022880B1 (ru) 2016-03-31
EP2262493A1 (en) 2010-12-22
PL2262493T3 (pl) 2015-08-31
WO2009109861A1 (en) 2009-09-11
HK1152247A1 (en) 2012-02-24
US20110003777A1 (en) 2011-01-06
AU2009220942A1 (en) 2009-09-11
PT2262493E (pt) 2015-06-02
EA201070913A1 (ru) 2011-04-29
CN102083428A (zh) 2011-06-01
EP2262493B1 (en) 2015-02-25
CA2717207A1 (en) 2009-09-11
ES2536208T3 (es) 2015-05-21
MX2010009642A (es) 2010-09-22
AU2009220942A8 (en) 2012-08-30
AU2009220942B2 (en) 2015-05-28
SI2262493T1 (sl) 2015-07-31

Similar Documents

Publication Publication Date Title
ES2790414T3 (es) Terapia de combinación con un inhibidor de topoisomerasa
ES2909741T3 (es) Tratamiento del cáncer
EP2063881B1 (en) A composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
Blumberg et al. Clinical trials of WR-2721 with radiation therapy
KR20150063070A (ko) 벨리노스타트 및 트라벡테딘을 사용한 병용 요법
ES2923929T3 (es) Formulación liposomal para uso en el tratamiento del cáncer
JP5642892B2 (ja) 多形膠芽腫の治療のためのマシテンタンを含有する組み合わせ剤
JP5615189B2 (ja) ベリノスタットの長期持続注入を用いた治療方法
ES3041602T3 (en) Pharmaceutical compositions of furosemide and uses thereof
ES2866636T3 (es) Composiciones farmacéuticas que comprenden paracetamol y proceso para preparar las mismas
WO2011064663A1 (en) Combination treatment employing belinostat and bicalutamide
CA3182613A1 (en) Use of mitoxantrone preparation in preparation of drug for diagnosing and treating breast cancer
BRPI0821739B1 (pt) sistema de liberação de droga para administração de uma substância anfifílica catiônica farmaceuticamente ativa compreendendo nanopartículas, composição farmacêutica e método de preparação de sistema de liberação de droga
AU2007284355A1 (en) Thiol-based agents for reducing toxicities associated with medical procedures employing radiographic contrast agents
KR20190134705A (ko) 향상된 안정성 및 생체이용률을 갖는 (ｅ)-2,4,6-트리메톡시스티릴-3-[(카복시메틸)아미노]-4-메톡시벤질설폰의 제형
JP2009539774A (ja) 薬物の投与方法
HK1152247B (en) Methods of treatment employing prolonged continuous infusion of belinostat
ES2864541T3 (es) Kit mejorado para la preparación de soluciones inyectables de carmustina
US20230210793A1 (en) Method for rapid infusion of carmustine

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20110426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131021

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140317

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140826

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140909

R150 Certificate of patent or registration of utility model

Ref document number: 5615189

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250